These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17693455)

  • 1. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin.
    Kim GB; Wang Z; Liu YY; Stavrou S; Mathias A; Goodwin KJ; Thomas JM; Neville DM
    Protein Eng Des Sel; 2007 Sep; 20(9):425-32. PubMed ID: 17693455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv.
    Wang Z; Kim GB; Woo JH; Liu YY; Mathias A; Stavrou S; Neville DM
    Bioconjug Chem; 2007; 18(3):947-55. PubMed ID: 17352456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion.
    Thompson J; Stavrou S; Weetall M; Hexham JM; Digan ME; Wang Z; Woo JH; Yu Y; Mathias A; Liu YY; Ma S; Gordienko I; Lake P; Neville DM
    Protein Eng; 2001 Dec; 14(12):1035-41. PubMed ID: 11809934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin.
    Ma S; Hu H; Thompson J; Stavrou S; Scharff J; Neville DM
    Bioconjug Chem; 1997; 8(5):695-701. PubMed ID: 9327133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.
    Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA
    Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.
    Wang Z; Duran-Struuck R; Crepeau R; Matar A; Hanekamp I; Srinivasan S; Neville DM; Sachs DH; Huang CA
    Bioconjug Chem; 2011 Oct; 22(10):2014-20. PubMed ID: 21866954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line.
    Liu YY; Gordienko I; Mathias A; Ma S; Thompson J; Woo JH; Neville DM
    Protein Expr Purif; 2000 Jul; 19(2):304-11. PubMed ID: 10873546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris.
    Woo JH; Liu YY; Mathias A; Stavrou S; Wang Z; Thompson J; Neville DM
    Protein Expr Purif; 2002 Jul; 25(2):270-82. PubMed ID: 12135560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted introduction of a diphtheria toxin resistant mutation into the chromosomal EF-2 locus of Pichia pastoris and expression of immunotoxin in the EF-2 mutants.
    Liu YY; Woo JH; Neville DM
    Protein Expr Purif; 2003 Aug; 30(2):262-74. PubMed ID: 12880776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18.
    Hamawy MM; Tsuchida M; Cho CS; Manthei ER; Fechner JH; Knechtle SJ
    Transplantation; 2001 Aug; 72(3):496-503. PubMed ID: 11502982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials.
    Woo JH; Liu JS; Kang SH; Singh R; Park SK; Su Y; Ortiz J; Neville DM; Willingham MC; Frankel AE
    Protein Expr Purif; 2008 Mar; 58(1):1-11. PubMed ID: 18160309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.
    Chowdhury PS; Vasmatzis G; Beers R; Lee B; Pastan I
    J Mol Biol; 1998 Sep; 281(5):917-28. PubMed ID: 9719644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
    J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.
    Vallera DA; Panoskaltsis-Mortari A; Jost C; Ramakrishnan S; Eide CR; Kreitman RJ; Nicholls PJ; Pennell C; Blazar BR
    Blood; 1996 Sep; 88(6):2342-53. PubMed ID: 8822957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
    Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
    Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice.
    Vallera DA; Todhunter D; Kuroki DW; Shu Y; Sicheneder A; Panoskaltsis-Mortari A; Vallera VD; Chen H
    Leuk Res; 2005 Mar; 29(3):331-41. PubMed ID: 15661270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
    Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
    J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.
    Woo JH; Lee YJ; Neville DM; Frankel AE
    Methods Mol Biol; 2010; 651():157-75. PubMed ID: 20686966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.